Online inquiry

IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14504MR)

This product GTTS-WQ14504MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CNR1 gene. The antibody can be applied in Non-alcoholic fatty liver disease (NAFLD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001160226.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1268
UniProt ID P21554
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ14504MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3537MR IVTScrip™ mRNA-Anti-APP, BART(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BART
GTTS-WQ1579MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-083
GTTS-WQ9697MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ6404MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ14613MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SC0001
GTTS-WQ1826MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ6998MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ15412MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TSR-022
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW